Updated Aug 7, 2026
/US Senate delays CLARITY Act vote to September, Thune confirms/Rocket Companies posts $766 million adjusted EBITDA in Q2 2026, most profitable quarter in four years/SoFi Technologies shares fall 28% in 2026 as lending revenue takes a larger share of the mix/Dan Mullen defends Florida record in Finebaum interview, but the closing stretch numbers cut against him/Palantir shares surge 16% after second-quarter commercial revenue draws "otherworldly" label/Nvidia weighs significant steps to address high-bandwidth memory chip shortage/US Senate delays CLARITY Act vote to September, Thune confirms/Rocket Companies posts $766 million adjusted EBITDA in Q2 2026, most profitable quarter in four years/SoFi Technologies shares fall 28% in 2026 as lending revenue takes a larger share of the mix/Dan Mullen defends Florida record in Finebaum interview, but the closing stretch numbers cut against him/Palantir shares surge 16% after second-quarter commercial revenue draws "otherworldly" label/Nvidia weighs significant steps to address high-bandwidth memory chip shortage

New Blood Test Detects 90% of Aggressive Prostate Cancer Cases, Outperforming Standard PSA Screening

A blood test called Stockholm3 detected 90% of aggressive prostate cancer cases in a clinical trial spanning more than 12,000 men, surpassing the traditional prostate-specific antigen test, which caught 74%, according to a study published…

By Mara Whitfield2 min read
Share